Yüklüyor......
Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
BACKGROUND: In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) trial, tolvaptan significantly reduced expansion of kidney volume and loss of kidney function. OBJECTIVE: To determine how benefits observed in the TEMPO trial migh...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3981098/ https://ncbi.nlm.nih.gov/pubmed/24042366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/0003-4819-159-6-201309170-00004 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|